The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | Incidence of second primary malignancies in lymphoma survivors
Sanjal Desai, MD, University of Minnesota Medical School, Minneapolis, MN, describes the results of a prospective cohort study exploring the incidence and factors associated with the risk of developing a second primary malignancy (SPM) in lymphoma survivors. When compared with the general population, lymphoma survivors had a lower likelihood of developing an SPM and a solid tumor, but had a higher chance of developing a therapy-related neoplasm. Treatment with chemotherapy and alkylating agents was associated with a higher likelihood of developing a second malignancy. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
